*Dear Editor*

A number of pneumonia cases of unknown causes have emerged in Wuhan, Hubei, China since December 2019.[@bib0001] After sequencing analysis of samples from the lower respiratory tract, a coronavirus,[@bib0002] which was last named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),[@bib0003] was newly discovered. On February 11, 2020, the World Health Organization (WHO) announced a new name for the disease caused by 2019-nCoV: coronavirus disease 2019 (COVID-19).[@bib0004] With the arrival of the Spring Festival, an epidemic SARS-CoV-2 infection has spread rapidly. It has swept across China and all over the world, and became a major global health concern. Chinese scientists found that SARS-CoV-2, like the SARS virus in 2003, enters human cells by recognizing angiotensin-converting enzyme 2 (ACE2) protein, which is the key to the invasion of the "new coronavirus" into the body.[@bib0005] Decreased ACE2 expression is a cause of hypertension because ACE2 is identified as a major angiotensin 1-7 (Ang1-7)-forming enzyme.[@bib0006] Based on studies of COVID-19, we found that hypertension initially occurs in many complications in COVID-19 patients.[@bib0007] However, limited reports on COVID-19 patients with hypertension are available in literature. Whether patients with hypertension who undergo angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy are more likely to suffer SARS-CoV-2 infection and whether ACEI/ARB therapy would have an influence on the clinical outcomes of patients with COVID-19 are controversy.[@bib0008] ^,^ [@bib0009] Moreover, the epidemiologic and clinical features of COVID-19 patients with hypertension are also not completely elucidated. Thus, in this study, we describe the demographic, epidemiologic, and clinical characteristics of COVID-19 patients with hypertension. And we also attempted to analyze whether ACEI/ARB treatment would have an influence on the clinical severity and outcomes of COVID-19 patients.

Altogether, 884 COVID-19 patients between January 17, 2020 and February 8, 2020, who confirmed with SARS-CoV-2 infection in Zhejiang Province, diagnosed as having COVID-19 according to WHO interim guidance[@bib0010] were enrolled in this study. Among various coexisting conditions, the proportion of patients with hypertension (149 patients, 16.86%) was higher than that of others. Compared with COVID-19 patients without hypertension, those patients with hypertension had a higher percentage of male sex (59.06% vs 49.93%, P=0.042), were older (57.00 years vs 43.00 years, P=0.000) and had a higher percentage of age ≥60 years (43.62% vs 13.88%, P=0.000). In this study, 723 patients were diagnosed to have a mild type; 123 patients, severe type; and 37 patients, critical type. Patients with hypertension had a lower rate of mild type (59.06% vs 86.39%, P=0.000), but had a higher rate of severe (26.17% vs 11.43%, P=0.001) and critical types (14.77% vs 2.04%, P=0.000) than patients without hypertension. Compared with patients without hypertension, patients with hypertension had a higher incidence of acute respiratory distress syndrome(ARDS) (24.16% vs 6.67%, P=0.000), were more likely to use glucocorticoids (31.54% vs 12.79%, P=0.000), antibiotic (50.33% vs 39.32%, P=0.013), and intravenous immune globulin therapy (21.48% vs 6.67%, P=0.000) and more likely to need mechanical ventilation (14.77% vs 2.04%, P=0.000) and intensive care unit (ICU) admission (16.11% vs 2.31%, P=0.000), extracorporeal membrane oxygenation (ECMO) (4.03% vs 0.82%, P=0.007) and continuous renal replacement therapy (CRRT) (2.01%vs 0.14%, P=0.016) therapy. The time intervals from illness onset to discharge and from admission to discharge in patients with hypertension (median 25.00 days and 20.00 days, respectively) were longer than those in patients without hypertension (median 22.00 days and 18.00 days, respectively) (P=0.000, P=0.002) ([Table 1](#tbl0001){ref-type="table"} ).Table 1Clinical characteristics of COVID-19 patients with and without hypertensionTable 1With Hypertension (n=149)Without Hypertension (n=735)*P*-Value^\#^Total (n=149)ACEI or ARB (n=65)Non-ACEI/ARB (n=84)*P*-Value\***Sex (male)**88 (59.06%)40 (61.54%)48 (57.14%)0.588367 (49.93%)0.042**Age (years)**57.00 (49.50-66.00)56.00 (48.00-64.00)58.00 (52.00-67.00)0.04343.00 (34.00-54.00)0.000≥60 yr65 (43.62%)25 (38.46%)40 (47.62%)0.264102 (13.88%)0.000**Coexisting Condition**Diabetes30 (20.13%)16 (24.62%)14 (16.67%)0.23035 (4.76%)0.000Heart disease7 (4.70%)2 (3.08%)5 (5.95%)0.4698 (1.09%)0.006COPD2 (1.34%)1 (1.54%)1 (1.19%)1.0003 (0.41%)0.200Chronic liver disease9 (6.04%)5 (7.69%)4 (4.76%)0.69126 (3.54%)0.153Chronic renal disease6 (4.03%)4 (6.15%)2 (2.38%)0.4042 (0.27%)0.000Cancer3 (2.01%)0 (0.00%)3 (3.57%)0.2576 (0.82%)0.379**Clinical Type**Mild Type88 (59.06%)37 (56.92%)51 (60.71%)0.641635 (86.39%)0.000Severe Type39 (26.17%)20 (30.77%)19 (22.62%)0.26284 (11.43%)0.000Critical Type22 (14.77%)8 (12.31%)14 (16.67%)0.45715 (2.04%)0.000**General symptoms**Fever127 (85.23%)58 (89.23%)69 (82.14%)0.226587 (79.86%)0.129Fatigue32 (21.48%)17 (26.15%)15 (17.86%)0.221126 (17.14%)0.208headache7 (4.70%)4 (6.15%)3 (3.57%)0.69974 (10.07%)0.038Muscle ache22 (14.77%)11 (16.92%)11 (13.10%)0.51477 (10.48%)0.130**Respiratory symptoms**Nasal obstruction3 (2.01%)1 (1.54%)2 (2.38%)1.00048 (6.53%)0.031Sore throat20 (13.42%)11 (16.92%)9 (10.71%)0.270103 (14.01%)0.849Cough100 (67.11%)47 (72.31%)53 (63.10%)0.235471 (64.08%)0.480Sputum production56 (37.58%)26 (40.00%)30 (35.71%)0.592245 (33.33%)0.318Hemoptysis7 (4.70%)5 (7.69%)2 (2.38%)0.2407 (0.95%)0.003Shortness of breath21 (14.09%)10 (15.38%)11 (13.10%)0.69020 (2.72%)0.000**Gastrointestinal symptoms**Nausea and vomiting7 (4.70%)4 (6.15%)3 (3.57%)0.69924 (3.27%)0.386Diarrhea12 (8.05%)7 (10.77%)5 (5.95%)0.28459 (8.03%)0.991**Complications**Acute respiratory distress syndrome36 (24.16%)16 (24.62%)20 (23.81%)0.90949 (6.67%)0.000Shock2 (1.34%)1 (1.54%)1 (1.19%)1.0002 (0.27%)0.134**Treatment**Glucocorticoids47 (31.54%)19 (29.23%)28 (33.33%)0.55994 (12.79%)0.000Antibiotic treatment75 (50.33%)31 (47.69%)44 (52.38%)0.570289 (39.32%)0.013Intravenous immune globulin therapy32 (21.48%)14 (21.54%)18 (21.43%)0.98749 (6.67%)0.000Admission to intensive care unit24 (16.11%)9 (13.85%)15 (17.86%)0.50917 (2.31%)0.000Mechanical ventilation22 (14.77%)8 (12.31%)14 (16.67%)0.45715 (2.04%)0.000EMCO6 (4.03%)3 (4.62%)3 (3.57%)1.0006 (0.82%)0.007CRRT3 (2.01%)1(1.54%)2 (2.38%)1.0001 (0.14%)0.016**Interval between illness onset to hospital outpatient (Days)**2.00(0.00-5.00)2.00(1.00-4.00)1.00(0.00-5.00)0.6882.00 (1.00-4.00)0.931**Interval between illness onset to admission (Days)**4.00(1.00-7.00)4.00(2.50-6.00)4.00(1.00-7.00)0.5483.00 (1.00-6.00)0.206**Interval between illness onset to confirmation (Days)**4.00(2.00-8.00)4.00(2.50-7.00)4.50(2.00-8.00)0.7824.00 (2.00-7.00)0.576**Interval between illness onset to discharge (Days)**25.00(19.00-32.00)26.00(18.25-32.00)25.00(19.00-31.50)0.95522.00(17.00-28.00)0.000**Interval between admission to discharge (Day)**20.00(14.00-27.00)20.50(14.00-26.75)20.00(14.50-27.00)0.91518.00(13.00-23.00)0.002**Death**1 (0.67%)1 (1.54%)0 (0.00%)0.4360 (0.00%)0.169**Laboratory detection**Leucocytes (× 10^9^ /L; normal range 4-10)5.40 (4.29-6.48)5.30 (4.26-6.32)5.45 (4.30-6.64)0.7494.70 (3.80-5.90)0.000Neutrophils (× 10^9^ /L; normal range 2-7)3.60 (2.80-4.80)3.43 (2.92-4.95)3.65 (2.71-4.79)0.9282.90 (2.20-3.83)0.000Lymphocyte (× 10^9^ /L; normal range 0.8-4.0)1.00 (0.71-1.37)0.96 (0.70-1.40)1.04 (0.77-1.33)0.8961.20 (0.90-1.60)0.000Platelets (× 10^9^ per L; normal range 83-303(Male), 101-320 (female)171.00 (138.00-220.50)166.00 (140.00-196.50)179.00 (137.00-225.50)0.336183.00 (149.00-223.00)0.095INR(normal range 0.85-1.15)1.02 (0.97-1.10)1.02 (0.97-1.11)1.02 (0.98-1.08)0.8711.01 (0.97-1.08)0.190Alb (g/L; normal range 40-55)40.34 (36.73-42.60)40.70 (37.2-42.89)39.20 (36.20-42.40)0.33941.30 (38.50-43.80)0.001ALT (U/L; normal range 9-50 (Male), 7-40 (Female))25.00 (18.20-39.00)26.00 (19.00-41.00)25.00 (17.00-32.75)0.37521.00 (15.00-33.00)0.001AST (U/L; normal range 15-40 (Male),13-35 (Female))28.00 (21.50-40.00)27.00 (19.95-40.10)28.00 (22.00-39.75)0.85725.00 (19.00-32.00)0.001TB (umol/L; normal range 0-26 (Male), 0-21 (Female))10.60 (7.70-14.95)11.40 (7.50-16.95)10.25 (7.73-14.40)0.7169.50 (6.90-13.10)0.010Scr (µmol/L; normal range: 57-97(Male), 41-73 (Female))72.00 (58.00-85.00)71.00 (57.00-85.25)73.00 (58.30-85.00)0.82966.00 (55.00-76.43)0.000BUN (mmol/L; normal range 3.1-8.0 (Male), 2.6-7.5 (Female)4.30(3.50-5.93)4.20 (3.31-5.71)4.33 (3.56-6.15)0.2773.77 (3.00-4.50)0.000CK (U/L; normal range 50-310 (Male), 40-200 (Female)83.00 (53.5-130.50)72.00 (49.50-131.00)90.00 (55.00-129.75)0.52169.00 (47.00-105.00)0.003LDH (U/L; normal range 120-250)250.00 (194.50-315.00)244.00 (181.00-318.00)253.00 (204.00-311.50)0.332211.00 (169.00-256.00)0.000Serum potassium (mmol/L; normal range 3.5-5.3)3.80 (3.50-4.05)3.84 (3.49-4.03)3.79 (3.50-4.06)0.5763.85 (3.60-4.14)0.031Serum sodium (mmol/L; normal range 137-147)137.00 (135.00-139.90)137.00 (135.14-139.85)137.15 (135.00-139.90)0.942138.60 (136.39-140.08)0.000CRP (mg/L; normal range 0-8)16.88 (7.20-44.55)21.00 (7.29-40.90)15.53 (6.39-51.00)0.5567.80 (2.30-19.00)0.000[^2][^3]

We found that the level of leukocyte count (median 5.40 × 10^9^/L vs 4.70 × 10^9^/L, P=0.000) and neutrophil count (median 3.60 × 10^9^/L vs 2.90 × 10^9^/L, P=0.000) was higher, but the level of lymphocyte count (median 1.00 × 10^9^/L vs 1.20 × 10^9^/L, P=0.000) was lower in patients with hypertension than in patients without hypertension. In terms of liver function, patients with hypertension had a lower level of albumin (median 40.34 vs 41.30, P=0.001), but a higher level of alanine aminotransferase (ALT)(median 25.00 vs 21.00, P=0.001), aspartate aminotransferase (AST) (median 28.00 vs 25.00, P=0.001), and total bilirubin (TB)(median 10.60 vs 9.50, P=0.010). As for renal function, patients with hypertension had a higher level of serum creatinine (Scr)(median 72.00 µmol/L vs 66.00µmol/L, P=0.000) and blood urea nitrogen (BUN) (median 4.30 mmol/L vs 3.77 mmol/L, P=0.000) . In addition, patients with hypertension had a higher level of creatine kinase (CK) (median 83.00 U/L vs 69 U/L, P=0.003), lactate dehydrogenase (LDH) (median 250.00 U/L vs 211 U/L, P=0.000), and C-reactive protein(CRP) (median 16.88 mg/L vs 7.80 mg/L, P=0.000), but lower level of serum potassium (median 3.80 mmol/L vs 3.85 mmol/L, P=0.031) and serum sodium (median 137.00 mmol/L vs 138.60 mmol/L, P=0.000). ([Table 1](#tbl0001){ref-type="table"})

Among the 149 patients with hypertension, most patients (102 patients) treated with CCB including 62 patients used CCB alone. 149 patients were divided into two groups according to whether or not ACEI or ARB included in the antihypertensive drug regimen, 65 patients in ACEI/ARB group and 84 patients in non-ACEI/ARB group. Compared with patients treated without ACEI/ARB, the clinical presentations and laboratory results between the two groups did not reach significant difference (all P\>0.05). No difference was found in severe/critical cases between patients with and those without ACEI/ARB treatment (all P\>0.05). There were no significant differences of the complication (Shock, ARDS), the treatments, including anti-coronavirus treatment, glucocorticoids treatment, antibiotic treatment, mechanical ventilation, ECMO, CRRT and so on (all P\>0.05). In addition, no difference was found in the rate of death, admission to ICU, interval between illness onset to discharge and the time of hospitalization (all P\>0.05). ([Table 1](#tbl0001){ref-type="table"}, [Fig. 1](#fig0001){ref-type="fig"} ).Fig. 1Clinical type, complications and outcome of COVID-19 patients with hypertension of different anti-hypertensive drugs.Fig. 1

In summary, we reported the largest cases of COVID-19 patients with hypertension. This study showed that patients with hypertension might have more severe respiratory symptoms, more abnormality laboratory indication, and more proportion of severe/critical type of COVID-19. Moreover, they may need more antibiotic, hormone, and intravenous immune globulin therapy and intensive care unit admission and have a longer hospital stay. Treatment with ACEI/ARB have no influence on the severity and the clinical outcome of COVID-19 patients with hypertention.
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